SELLAS Nears Phase 3 REGAL Trigger as Shares Jump 7%
SLS has more than doubled off its 52-week low of $1.39.
Summary
SELLAS is approaching the 80-death event trigger for its pivotal Phase 3 REGAL trial, with final analysis expected soon. The stock rose 7% to $12.31 on the news, ending a three-quarter decline. Phase 2 data for SLS009 (tambiciclib) is due in Q4, adding another near-term catalyst. The company's cash position of $138.3 million from the August 10-Q provides runway through these readouts. Traders are also watching for possible deal activity given the HQ lease through September 2027.
At the time of this announcement, SLS was trading at $12.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $1.39 to $15.88. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.